NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, today announced a partnership with neuroscience ...

Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Naïve Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB) Patients were ...

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase ...

Clinical research and health tech companies Medidata and Cogstate are joining forces to speed up trials and improve outcomes measurement across diseases of the central nervous system, the partners ...

Central nervous system (CNS) clinical trials are among the most scientifically complex and operationally demanding in life sciences. The need to evaluate nuanced cognitive, behavioral, and emotional ...

Partnership launched under MTEA to evaluate the potential of Vect-Horus technology to deliver siRNAs into the CNS Assessment of BBB shuttle-siRNA compatibility, CNS delivery efficiency, and ...